BG107745A - Инхибиране на зависимостта на туморни клетки от растежния фактор - Google Patents

Инхибиране на зависимостта на туморни клетки от растежния фактор Download PDF

Info

Publication number: BG107745A
Authority: BG; Bulgaria
Prior art keywords: use according; group; tumor cells; cells; egf
Prior art date: 2000-10-18

Application number

BG107745A

Other languages

Bulgarian (bg)

English (en)

Inventor

Rosemarie Lichtner

Ulrike Fuhrmann

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2003-04-18

Publication date

2004-01-30

2000-10-18 Priority claimed from DE10051609A external-priority patent/DE10051609A1/de

2003-04-18 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2004-01-30 Publication of BG107745A publication Critical patent/BG107745A/bg

Links

210000004881 tumor cell Anatomy 0.000 title claims abstract description 17
239000003102 growth factor Substances 0.000 title claims description 16
230000005764 inhibitory process Effects 0.000 title abstract description 3
102000003998 progesterone receptors Human genes 0.000 claims abstract description 33
108090000468 progesterone receptors Proteins 0.000 claims abstract description 33
239000003112 inhibitor Substances 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 39
230000027455 binding Effects 0.000 claims description 18
230000012010 growth Effects 0.000 claims description 15
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 11
206010006187 Breast cancer Diseases 0.000 claims description 10
208000026310 Breast neoplasm Diseases 0.000 claims description 10
230000001419 dependent effect Effects 0.000 claims description 10
150000001875 compounds Chemical class 0.000 claims description 9
150000003254 radicals Chemical class 0.000 claims description 8
102000001301 EGF receptor Human genes 0.000 claims description 7
108060006698 EGF receptor Proteins 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
230000003637 steroidlike Effects 0.000 claims description 6
-1 fluoroalkyl steroids Chemical class 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 4
230000035755 proliferation Effects 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
206010061309 Neoplasm progression Diseases 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
150000005840 aryl radicals Chemical class 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
125000001589 carboacyl group Chemical group 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
230000005751 tumor progression Effects 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims 1
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 23
229940126062 Compound A Drugs 0.000 description 12
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 8
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000000186 progesterone Substances 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 5
230000001833 anti-estrogenic effect Effects 0.000 description 5
229960005309 estradiol Drugs 0.000 description 5
229930182833 estradiol Natural products 0.000 description 5
102000015694 estrogen receptors Human genes 0.000 description 5
108010038795 estrogen receptors Proteins 0.000 description 5
229950011093 onapristone Drugs 0.000 description 5
239000000126 substance Substances 0.000 description 5
229940046836 anti-estrogen Drugs 0.000 description 4
239000000328 estrogen antagonist Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 3
239000000333 selective estrogen receptor modulator Substances 0.000 description 3
229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
239000003270 steroid hormone Substances 0.000 description 3
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000003418 antiprogestin Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000000694 effects Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
238000013391 scatchard analysis Methods 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
239000002970 Calcium lactobionate Substances 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
101150082819 ERBB3 gene Proteins 0.000 description 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
230000005284 excitation Effects 0.000 description 1
229940087861 faslodex Drugs 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
229950002366 nafoxidine Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
230000003623 progesteronic effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG107745A 2000-10-18 2003-04-18 Инхибиране на зависимостта на туморни клетки от растежния фактор BG107745A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24101000P	2000-10-18	2000-10-18
DE10051609A DE10051609A1 (de)	2000-10-18	2000-10-18	Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en)	2000-10-18	2001-10-17	Use of inhibitors of progesterone receptor for treating cancer

Publications (1)

Publication Number	Publication Date
BG107745A true BG107745A (bg)	2004-01-30

Family

ID=26007397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107745A BG107745A (bg)	2000-10-18	2003-04-18	Инхибиране на зависимостта на туморни клетки от растежния фактор

Country Status (25)

Country	Link
EP (1)	EP1414465B1 (cs)
JP (1)	JP4335525B2 (cs)
KR (1)	KR20030044006A (cs)
CN (1)	CN1311833C (cs)
AT (1)	ATE339208T1 (cs)
AU (2)	AU2002215958B2 (cs)
BG (1)	BG107745A (cs)
BR (1)	BR0114677A (cs)
CA (1)	CA2423013A1 (cs)
CY (1)	CY1106289T1 (cs)
CZ (1)	CZ299945B6 (cs)
DE (1)	DE60123138T2 (cs)
DK (1)	DK1414465T3 (cs)
EA (1)	EA005945B1 (cs)
EE (1)	EE200300156A (cs)
ES (1)	ES2272561T3 (cs)
HR (1)	HRP20030386A2 (cs)
HU (1)	HUP0301461A3 (cs)
IL (2)	IL154974A0 (cs)
MX (1)	MXPA03002953A (cs)
NO (1)	NO20031745L (cs)
NZ (1)	NZ545965A (cs)
PL (1)	PL366415A1 (cs)
SK (1)	SK4752003A3 (cs)
WO (1)	WO2002032429A2 (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102006054535A1 (de) *	2006-11-15	2008-05-21	Bayer Schering Pharma Aktiengesellschaft	Progesteronrezeptorantagonisten
DE102009034362A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de)	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0466315A3 (en) *	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) *	1991-12-17	1993-08-24	Schering Corporation	Inhibitors of platelet-derived growth factor
DE19706061A1 (de) *	1997-02-07	1998-08-13	Schering Ag	Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) *	1997-12-23	2001-05-02	Schering Ag	11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
FR2789393B1 (fr) *	1999-02-05	2001-10-12	Centre Nat Rech Scient	Lactol steroidique

2001
- 2001-10-17 HR HR20030386A patent/HRP20030386A2/hr not_active Application Discontinuation
- 2001-10-17 DE DE60123138T patent/DE60123138T2/de not_active Expired - Fee Related
- 2001-10-17 PL PL01366415A patent/PL366415A1/xx not_active Application Discontinuation
- 2001-10-17 EA EA200300468A patent/EA005945B1/ru not_active IP Right Cessation
- 2001-10-17 BR BR0114677-7A patent/BR0114677A/pt not_active Application Discontinuation
- 2001-10-17 WO PCT/EP2001/012004 patent/WO2002032429A2/en not_active Ceased
- 2001-10-17 EE EEP200300156A patent/EE200300156A/xx unknown
- 2001-10-17 EP EP01987667A patent/EP1414465B1/en not_active Expired - Lifetime
- 2001-10-17 DK DK01987667T patent/DK1414465T3/da active
- 2001-10-17 AU AU2002215958A patent/AU2002215958B2/en not_active Ceased
- 2001-10-17 AU AU1595802A patent/AU1595802A/xx active Pending
- 2001-10-17 AT AT01987667T patent/ATE339208T1/de not_active IP Right Cessation
- 2001-10-17 JP JP2002535667A patent/JP4335525B2/ja not_active Expired - Fee Related
- 2001-10-17 SK SK475-2003A patent/SK4752003A3/sk unknown
- 2001-10-17 CZ CZ20031071A patent/CZ299945B6/cs not_active IP Right Cessation
- 2001-10-17 IL IL15497401A patent/IL154974A0/xx active IP Right Grant
- 2001-10-17 MX MXPA03002953A patent/MXPA03002953A/es active IP Right Grant
- 2001-10-17 HU HU0301461A patent/HUP0301461A3/hu unknown
- 2001-10-17 NZ NZ545965A patent/NZ545965A/en unknown
- 2001-10-17 CN CNB018173853A patent/CN1311833C/zh not_active Expired - Fee Related
- 2001-10-17 KR KR10-2003-7005358A patent/KR20030044006A/ko not_active Ceased
- 2001-10-17 CA CA002423013A patent/CA2423013A1/en not_active Abandoned
- 2001-10-17 ES ES01987667T patent/ES2272561T3/es not_active Expired - Lifetime
2003
- 2003-03-18 IL IL154974A patent/IL154974A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031745A patent/NO20031745L/no not_active Application Discontinuation
- 2003-04-18 BG BG107745A patent/BG107745A/bg unknown
2006
- 2006-12-12 CY CY20061101786T patent/CY1106289T1/el unknown

Also Published As

Publication number	Publication date
ES2272561T3 (es)	2007-05-01
CN1551772A (zh)	2004-12-01
ATE339208T1 (de)	2006-10-15
NO20031745D0 (no)	2003-04-15
NZ545965A (en)	2007-09-28
DK1414465T3 (da)	2007-01-29
EE200300156A (et)	2003-08-15
CZ299945B6 (cs)	2008-12-29
HUP0301461A2 (hu)	2003-10-28
EA005945B1 (ru)	2005-08-25
SK4752003A3 (en)	2003-10-07
HK1071697A1 (en)	2005-07-29
IL154974A0 (en)	2003-10-31
JP2004513094A (ja)	2004-04-30
EP1414465B1 (en)	2006-09-13
WO2002032429A2 (en)	2002-04-25
BR0114677A (pt)	2003-10-07
WO2002032429A3 (en)	2004-02-19
CY1106289T1 (el)	2011-10-12
HUP0301461A3 (en)	2010-01-28
MXPA03002953A (es)	2003-08-07
IL154974A (en)	2007-05-15
EA200300468A1 (ru)	2003-10-30
DE60123138D1 (de)	2006-10-26
JP4335525B2 (ja)	2009-09-30
AU1595802A (en)	2002-04-29
HRP20030386A2 (en)	2005-04-30
DE60123138T2 (de)	2007-09-13
EP1414465A2 (en)	2004-05-06
AU2002215958C1 (en)	2002-04-29
AU2002215958B2 (en)	2006-08-17
PL366415A1 (en)	2005-01-24
NO20031745L (no)	2003-04-15
CA2423013A1 (en)	2002-04-25
CN1311833C (zh)	2007-04-25
KR20030044006A (ko)	2003-06-02

Publication	Publication Date	Title
Leung et al.	2017	Non-genomic actions of the androgen receptor in prostate cancer
Jaiyesimi et al.	1995	Use of tamoxifen for breast cancer: twenty-eight years later.
Sutherland et al.	1988	Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells
US5545634A (en)	1996-08-13	Activation of androgen receptors with low dose non-masculinizing androgenic compounds
Schwartz et al.	1995	Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women
Bajetta et al.	1999	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Christ et al.	1998	Cardiovascular steroid actions: swift swallows or sluggish snails?
BG107745A (bg)	2004-01-30	Инхибиране на зависимостта на туморни клетки от растежния фактор
US20040157811A1 (en)	2004-08-12	Inhibition of the growth factor dependency of tumor cells
EP1272195B1 (en)	2005-10-12	Use of fulvestrant in the treatment of resistant breast cancer
Kamaraju et al.	2021	Leveraging antiprogestins in the treatment of metastatic breast cancer
AU2002215958A1 (en)	2002-07-04	Use of inhibitors of progesterone receptor for treating cancer
AU2001244372A1 (en)	2002-01-03	Use of fulvestrant in the treatment of resistant breast cancer
Osborne et al.	2005	Aromatase inhibitors: future directions
HK1071697B (en)	2007-08-03	Inhibition of the growth factor dependency of tumor cells
UA76128C2 (en)	2006-07-17	Use of progesterone receptor inhibitors for treating steroid-resistant breast cancer
Clarke et al.	2012	1986) and calmodulin (Lam, 1984) is inhibited by Tamoxifen as a result of direct interactions. Structural parameters of the plasma
Clarke et al.	1996	influence its biological activity and that, when significantly altered, could contribute to the emergence of an antiestrogen resistant phenotype. These
Banerjee	2011	The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer
Chabner et al.	1976	National Cancer Institute, Frank J. Rauscher, Jr., Director Division of Cancer Treatment, Vincent T. DeVita, Jr., Director
Friedl et al.	1991	The Role of Prolonged Antihormonal Treatment of Breast Cancer: A Strategy for Adjuvant Therapy
Veronesi et al.	1991	New developments in breast cancer research